Reunion Biotech Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $10.1M

  • Investors
  • 9

Reunion Biotech General Information

Description

Developer of medical hydrogel products intended to provide new medical solutions. The company provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolism and innovative anti-tumor drugs, enabling clients with self-developed ready-to-use PEG hydrogel materials.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 221, 2nd Floor, Building 5
  • Number 1180 Xingxian Road, Jiading District
  • Shanghai, 201821
  • China
+86 021
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 221, 2nd Floor, Building 5
  • Number 1180 Xingxian Road, Jiading District
  • Shanghai, 201821
  • China
+86 021

Reunion Biotech Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reunion Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 28-Feb-2026 $10.1M Completed Generating Revenue
6. Later Stage VC (Series B) 19-Jan-2024 Completed Generating Revenue
5. Early Stage VC (Series A1) 23-Sep-2022 Completed Generating Revenue
4. Early Stage VC (Series A) 23-Dec-2021 Completed Generating Revenue
3. Early Stage VC 15-Jul-2021 Completed Generating Revenue
2. Early Stage VC 12-Jan-2021 $1.53M $1.53M Completed Generating Revenue
1. Accelerator/Incubator 17-Dec-2018 Completed Startup
To view Reunion Biotech’s complete valuation and funding history, request access »

Reunion Biotech Patents

Reunion Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026137930-A1 Pelvic organ group module for ct-guidable puncture injection via posterior fornix of vagina Pending 27-Dec-2024
US-20260355389-A1 Double-network soft tissue filling medical hydrogel, preparation method therefor, and use thereof Pending 29-Dec-2023
WO-2025139024-A1 Double-network soft tissue filling medical hydrogel, preparation method therefor, and use thereof Inactive 29-Dec-2023
WO-2025055386-A1 Two-component in-situ-curing heat-insulating hydrogel containing gas microspheres, and preparation method therefor Inactive 12-Sep-2023
US-20250129218-A1 Hydrogel kit capable of being quickly dissolved as required and use method thereof Pending 22-Aug-2023 C08J3/075
To view Reunion Biotech’s complete patent history, request access »

Reunion Biotech Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Dingxin Capital Venture Capital Minority
Qingdao Conson Financial Holdings Venture Capital Minority
Jiaxing Deshi Private Equity Fund Management Growth/Expansion Minority
Qiming Venture Partners Venture Capital Minority
Proxima Capital Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Reunion Biotech FAQs

  • When was Reunion Biotech founded?

    Reunion Biotech was founded in 2018.

  • Where is Reunion Biotech headquartered?

    Reunion Biotech is headquartered in Shanghai, China.

  • What industry is Reunion Biotech in?

    Reunion Biotech’s primary industry is Therapeutic Devices.

  • Is Reunion Biotech a private or public company?

    Reunion Biotech is a Private company.

  • What is Reunion Biotech’s current revenue?

    The current revenue for Reunion Biotech is .

  • How much funding has Reunion Biotech raised over time?

    Reunion Biotech has raised $31M.

  • Who are Reunion Biotech’s investors?

    Dingxin Capital, Qingdao Conson Financial Holdings, Jiaxing Deshi Private Equity Fund Management, Qiming Venture Partners, and Proxima Capital are 5 of 9 investors who have invested in Reunion Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process